Literature DB >> 2354448

Reversal of multidrug resistance by lipophilic drugs.

E Hofsli1, J Nissen-Meyer.   

Abstract

The phenomenon of multidrug resistance implies that a wide spectrum of structurally and functionally unrelated chemotherapeutic drugs are recognized and processed by the molecular system which protects multidrug-resistant (MDR) cells against lipophilic cytotoxic drugs. This suggests that lipophilic agents with low toxicity may also be recognized and processed by this molecular system. At high concentrations these agents might saturate the system, thereby reversing multidrug resistance. In support of this hypothesis, 19 (73%) of 26 arbitrarily chosen lipophilic drugs were in this study found to increase the accumulation of actinomycin D in MDR WEHI 164 cells. The most potent of these drugs were also shown to sensitize these cells to the cytotoxic effect of actinomycin D and doxorubicin. There was a good correlation between the ability of the lipophilic drugs to induce an increased accumulation of actinomycin D in MDR cells and their ability to sensitize these cells to the cytotoxic effect of chemotherapeutic drugs. The ability to reverse drug resistance appeared to be additive, since increased accumulation of actinomycin D was also obtained by combining low concentrations of various lipophilic drugs. This may be a way to reduce the in vivo toxic effect of the lipophilic drugs yet still obtain a reversal of drug resistance. When MDR cells were exposed to lipophilic drugs which reversed drug resistance, the synergistic cytotoxic effect of actinomycin D and tumor necrosis factor was obtained at reduced actinomycin D concentrations.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2354448

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  19 in total

Review 1.  Cellular drug efflux and reversal therapy of cancer.

Authors:  P W Wigler
Journal:  J Bioenerg Biomembr       Date:  1996-06       Impact factor: 2.945

2.  Transport of celiprolol across human intestinal epithelial (Caco-2) cells: mediation of secretion by multiple transporters including P-glycoprotein.

Authors:  J Karlsson; S M Kuo; J Ziemniak; P Artursson
Journal:  Br J Pharmacol       Date:  1993-11       Impact factor: 8.739

3.  Effects of steroids and verapamil on P-glycoprotein ATPase activity: progesterone, desoxycorticosterone, corticosterone and verapamil are mutually non-exclusive modulators.

Authors:  S Orlowski; L M Mir; J Belehradek; M Garrigos
Journal:  Biochem J       Date:  1996-07-15       Impact factor: 3.857

4.  Reversal of multidrug resistance by phenothiazines and structurally related compounds.

Authors:  A Ramu; N Ramu
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

Review 5.  Positron emission tomography studies on binding of central nervous system drugs and P-glycoprotein function in the rodent brain.

Authors:  Philip H Elsinga; N Harry Hendrikse; Joost Bart; Aren van Waarde; Willem Vaalburg
Journal:  Mol Imaging Biol       Date:  2005 Jan-Feb       Impact factor: 3.488

6.  Enhanced oral bioavailability of paclitaxel by coadministration of the P-glycoprotein inhibitor KR30031.

Authors:  Jong Soo Woo; Chang Hyun Lee; Chang Koo Shim; Sung-Joo Hwang
Journal:  Pharm Res       Date:  2003-01       Impact factor: 4.200

7.  Influence of cytokines on mdr1 expression in human colon carcinoma cell lines: increased cytotoxicity of MDR relevant drugs.

Authors:  W Walther; U Stein
Journal:  J Cancer Res Clin Oncol       Date:  1994       Impact factor: 4.553

8.  In vitro and in situ absorption of SDZ-RAD using a human intestinal cell line (Caco-2) and a single pass perfusion model in rats: comparison with rapamycin.

Authors:  A Crowe; M Lemaire
Journal:  Pharm Res       Date:  1998-11       Impact factor: 4.200

9.  Non-glucocorticoid steroid analogues (21-aminosteroids) sensitize multidrug resistant cells to vinblastine.

Authors:  I Abraham; C L Wolf; K E Sampson
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

10.  Decreased resistance to N,N-dimethylated anthracyclines in multidrug-resistant Friend erythroleukemia cells.

Authors:  A Schaefer; J Westendorf; K Lingelbach; C A Schmidt; D L Mihalache; A Reymann; H Marquardt
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.